One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial Read More Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib Read More Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665 Read More Click Here To Contact Us If You Cannot Access An Article
